RNA Therapeutics: Why CMC Strategy Will Define The Next Decade

By Azizul Haque, Ph.D., director, PR&D, DSDM, Syngene International Ltd.

RNA therapeutics are increasingly being recognized not as a collection of individual products but as a programmable industrial platform. Unlike traditional pharmaceuticals, where each molecule often requires its own development and manufacturing paradigm, many RNA modalities share common design principles, manufacturing workflows, analytical approaches, and delivery technologies, allowing the same underlying system to generate multiple therapeutic products.

As a result, value increasingly resides not only in individual therapeutic candidates but also in the systems capable of repeatedly converting genetic information into medicines. This transition has profound implications for investors, developers, regulators, and CRDMOs alike because platforms ultimately compete on execution, scalability, and reliability rather than discovery alone.

The rapid emergence of mRNA vaccines, siRNA therapeutics, antisense technologies, and next-generation RNA platforms has demonstrated something important: while significant scientific challenges remain, the center of gravity is shifting from proof of concept toward industrialization. The question now is whether RNA therapeutics can be industrialized.

Bridging Discovery To Platform

For much of the past three decades, RNA existed more as scientific possibility than pharmaceutical reality. The challenge was not simply understanding the biology. RNA is inherently fragile, difficult to deliver, and highly sensitive to manufacturing conditions. Progress required advances in delivery technologies, analytical characterization, process engineering, and manufacturing science.

The COVID-19 pandemic provided both validation and perspective. It demonstrated that RNA medicines could be developed and deployed at unprecedented speed. It also revealed that manufacturing capacity, supply chain resilience, technology transfer, and operational readiness could become limiting factors even when the science succeeded.

This pattern is familiar. Across small molecules, biologics, and other advanced modalities, pharmaceutical innovation follows a predictable evolution. The industry first focuses on molecules. Then it focuses on processes. Eventually it learns that sustainable success depends on systems. RNA therapeutics are entering that third phase now.

Discovery Is No Longer The Hard Part

The biotechnology industry celebrates discovery for good reason. New targets, novel mechanisms, and breakthrough biology remain the foundation of therapeutic innovation. Yet the transition from laboratory success to commercial product remains one of the most underestimated challenges in pharmaceutical development.

Scientists ask whether something works. Investors ask whether it creates value. Regulators ask whether safety, quality, and efficacy can be demonstrated consistently. Manufacturing organizations ask whether it can be produced repeatedly, economically, and reliably at scale. These questions are rarely answered at the same time. The gap between them is where many development failures occur.

Consider Alnylam’s patisiran, the first approved siRNA therapeutic. The biological promise of RNA interference had been recognized for years. Translating that promise into a product required advances in delivery technology, lipid nanoparticle manufacturing, analytical characterization, process reproducibility, and regulatory alignment. The science was not the ultimate constraint. The system was.

Manufacturability cannot remain an afterthought. It must become part of how innovation is conceived, not merely how it is executed.

Four Realities That Will Shape The Next Generation Of RNA Programs

Scale Is A Strategic Decision

One of the most persistent misconceptions in therapeutic development is that laboratory success predicts commercial success, but scale changes everything. Reactionary behavior, process variability, economics, sourcing requirements, and operational risk all evolve as programs move toward commercialization.

The 2021–2022 capacity crunch across mRNA CDMOs offered a second illustration. Demand for lipid nanoparticle formulation and fill/finish capacity outstripped supply almost overnight, and organizations that had treated scale-up as someone else’s problem found themselves competing for the same limited slots, the same specialized lipids, and the same trained operators. The constraint was rarely the molecule. It was capacity that had not been planned far enough in advance.

The experience of mRNA vaccine manufacturing demonstrated this clearly. Scientific success created opportunity. Manufacturing readiness determined whether that opportunity could be captured. Organizations that ask scale-up questions early gain a decisive advantage.

Analytical Understanding Matters More Than Analytical Testing

RNA manufacturing generates complex impurity profiles, variants, and structural attributes. But the challenge is not merely measuring them. It is understanding them.

Organizations that invest early in analytical understanding reduce downstream development risk, accelerate regulatory interactions, and strengthen commercial robustness. Analytical science is increasingly becoming a strategic capability rather than a support function.

Delivery Is Also A Manufacturing Problem

Much of the discussion around RNA focuses on delivery biology and rightfully so. But delivery systems must also be manufactured reproducibly.

Lipid nanoparticles are not simply formulation technologies. They are products of manufacturing systems. Particle size, encapsulation efficiency, composition, and stability all depend on process control. Biological performance and manufacturing performance are inseparable.

Supply Chains And Regulatory Systems Have Become Competitive Assets

RNA therapeutics depend on specialized enzymes, nucleotides, plasmids, lipids, analytical standards, and highly specialized consumables. The pandemic highlighted a critical lesson: scientific innovation can move faster than supply chains. The same principle increasingly applies to regulation.

Emerging personalized cancer vaccines offer a glimpse into this future. Programs such as the individualized neoantigen therapies advancing through late-stage development illustrate what “approving the system” actually requires: each batch is a unique product, manufactured against a compressed clinical timeline, for a single patient. Manufacturing timelines, analytical release strategies, supply chain responsiveness, and regulatory oversight become tightly interconnected — not as abstractions but as the literal sequence between a tumor biopsy and a dose in the clinic.

As agencies gain experience with RNA modalities, approval depends not only on demonstrating a product but also on demonstrating confidence in the system that produces it.

Organizations that build resilient supply chains and robust development frameworks early will possess a meaningful advantage.

Why CRDMOs Have Become Central

The evolution from CDMO to CRDMO is more than a change in terminology. It reflects a shift in where value is created. RNA therapeutics require integrated expertise across development science, analytics, process engineering, regulatory strategy, technology transfer, and commercial operations. At its best, the CRDMO becomes an architect of integration. It helps innovators design what can ultimately be manufactured rather than merely manufacturing what has already been designed.

Continuity of knowledge remains one of the most undervalued assets in development. When analytical understanding, process knowledge, technology transfer, and commercial manufacturing remain connected, organizations preserve the tacit knowledge that often determines long-term success.

The most effective partnerships are not transactional. They are developmental. Their value lies not merely in execution but in helping organizations avoid problems before they emerge.

In practice, this looks less like a vendor relationship and more like a shared development team. Consider a process handed over from a sponsor’s lab to a CRDMO for scale-up. A transactional engagement treats the lab process as fixed and asks only how to reproduce it at larger scale.

A developmental one asks a different question first: why does this step behave the way it does, and will that behavior hold at 10 times the volume?

That second conversation — uncomfortable, often initiated by the CRDMO rather than requested by the sponsor — is where a borderline impurity profile gets caught before a regulatory filing, where a raw material with a single supplier gets flagged before it becomes a stockout, where a step that worked at gram scale because of how heat dissipated in a small vessel gets redesigned before it fails at kilogram scale.

None of this requires new science. It requires a relationship in which the CRDMO is brought in early enough, and trusted enough, to ask the question — and a sponsor willing to hear an uncomfortable answer well before the timeline makes it expensive.

The Next Chapter

There is reason for optimism. The RNA industry has repeatedly solved challenges once considered insurmountable. Stability, delivery, manufacturability, and scale have all advanced dramatically. The ecosystem supporting RNA development is broader and more experienced than at any point in its history.

What makes the coming decade particularly important is that the remaining barriers are increasingly organizational rather than conceptual. Success will depend less on proving that RNA can work and more on building integrated systems capable of translating innovation into reliable, affordable, and globally accessible medicines.

The first chapter of the RNA revolution was written by scientists who challenged biological limits. The next chapter will be written by organizations that master complexity across development, analytics, manufacturing, supply chains, regulatory science, and commercialization.

The risk in RNA therapeutics is increasingly not in the biology. It is in the system. The future of RNA therapeutics will not be determined solely by the quality of discovery. It will be determined by the quality of integration. In that future, CMC is no longer a support function. It is the operating system that transforms genetic information into accessible medicines.

About The Author:

Azizul Haque, Ph.D., is a pharmaceutical development and CMC leader with more than three decades of experience spanning API and NCE process development, technology transfer, CRDMO operations, and the strategic development, manufacturing, commercialization, and life cycle management of advanced therapeutic modalities, having led multidisciplinary programs across small molecules and emerging therapeutic platforms. He holds a doctorate in organic chemistry from the Indian Association for the Cultivation of Science (IACS), Kolkata, and completed research appointments at UCLA, the University of California Riverside, and the National Institute for Nanotechnology (NINT), Alberta.